Relative and Absolute Bioavailability of Prednisone and Prednisolone After Separate Oral and Intravenous Doses
Overview
Affiliations
A randomized, four-way cross-over study was conducted in eight healthy male volunteers to determine the relative and absolute bioavailability of prednisone (PN) and prednisolone (PL). PN and PL were administered as single, oral 10-mg tablet doses and as 10-mg zero-order 0.5-hour intravenous infusions. Comparable mean PN and PL maximum plasma concentrations (Cmax), times for Cmax, areas under the plasma concentration-time curves (AUC), and apparent elimination rate constants between tablet treatments demonstrated that PN and PL tablets were bioequivalent. Absolute bioavailability (F) determinations based on plasma PL concentrations were independent of which IV treatment was used as reference and indicated complete systemic availability of PL from both PN and PL tablets. However, F based on plasma PN data was contradictory. Using IV PN as reference, approximately 70% systemic availability was observed from both tablets, whereas using IV PL as reference, systemic availability was greater than unity. PN and PL are model compounds that exemplify the difficulties involved in accurately determining the relative and absolute bioavailability of substances that undergo reversible metabolism.
Effect of hypoalbuminemia on drug pharmacokinetics.
Idasiak-Piechocka I, Lewandowski D, Swigut W, Kalinowski J, Mikosza K, Suchowiejski P Front Pharmacol. 2025; 16:1546465.
PMID: 40051558 PMC: 11882431. DOI: 10.3389/fphar.2025.1546465.
Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review.
Caetano C, Malchoff C Front Endocrinol (Lausanne). 2022; 13:897211.
PMID: 35846313 PMC: 9276933. DOI: 10.3389/fendo.2022.897211.
Empiric Determination of the Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency.
Caetano C, Sliwinska A, Madhavan P, Grady J, Malchoff C J Endocr Soc. 2020; 4(11):bvaa145.
PMID: 33123657 PMC: 7575132. DOI: 10.1210/jendso/bvaa145.
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.
Berends S, Strik A, Lowenberg M, DHaens G, Mathot R Clin Pharmacokinet. 2018; 58(1):15-37.
PMID: 29752633 PMC: 6326086. DOI: 10.1007/s40262-018-0676-z.
Five things every community pharmacist should know when dispensing for 4-legged patients.
Frankel G, Kusno A, Louizos C Can Pharm J (Ott). 2016; 149(2):99-106.
PMID: 27076821 PMC: 4813516. DOI: 10.1177/1715163516628543.